Technical Analysis for ACXP - Acurx Pharmaceuticals, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Wide Bands | Range Expansion | 4.72% | |
Oversold Stochastic | Weakness | 4.72% | |
NR7 | Range Contraction | 17.31% | |
Narrow Range Bar | Range Contraction | 17.31% | |
Inside Day | Range Contraction | 17.31% | |
Wide Bands | Range Expansion | 17.31% | |
Oversold Stochastic | Weakness | 17.31% | |
Lower Bollinger Band Walk | Weakness | 16.75% | |
Wide Bands | Range Expansion | 16.75% | |
Oversold Stochastic | Weakness | 16.75% |
Alert | Time |
---|---|
Possible Inside Day | about 3 hours ago |
60 Minute Opening Range Breakdown | about 6 hours ago |
2x Volume Pace | about 7 hours ago |
1.5x Volume Pace | about 7 hours ago |
Gap Up Partially Closed | about 7 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/10/2024
Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. The company was founded in 2017 and is based in Staten Island, New York.
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Care Antibiotics Bacterial Infections Staphylococcus Aureus Methicillin Gram Positive Bacteria Vancomycin
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Care Antibiotics Bacterial Infections Staphylococcus Aureus Methicillin Gram Positive Bacteria Vancomycin
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 8.82 |
52 Week Low | 1.17 |
Average Volume | 177,284 |
200-Day Moving Average | 2.96 |
50-Day Moving Average | 3.05 |
20-Day Moving Average | 2.59 |
10-Day Moving Average | 2.27 |
Average True Range | 0.25 |
RSI (14) | 39.39 |
ADX | 30.67 |
+DI | 18.63 |
-DI | 25.66 |
Chandelier Exit (Long, 3 ATRs) | 2.61 |
Chandelier Exit (Short, 3 ATRs) | 2.58 |
Upper Bollinger Bands | 3.35 |
Lower Bollinger Band | 1.84 |
Percent B (%b) | 0.33 |
BandWidth | 58.31 |
MACD Line | -0.28 |
MACD Signal Line | -0.25 |
MACD Histogram | -0.0284 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.92 | ||||
Resistance 3 (R3) | 2.89 | 2.66 | 2.82 | ||
Resistance 2 (R2) | 2.66 | 2.52 | 2.68 | 2.79 | |
Resistance 1 (R1) | 2.50 | 2.42 | 2.58 | 2.53 | 2.75 |
Pivot Point | 2.27 | 2.27 | 2.32 | 2.29 | 2.27 |
Support 1 (S1) | 2.11 | 2.12 | 2.19 | 2.13 | 1.91 |
Support 2 (S2) | 1.88 | 2.03 | 1.90 | 1.87 | |
Support 3 (S3) | 1.72 | 1.88 | 1.84 | ||
Support 4 (S4) | 1.74 |